

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 12 Match STN Content and Features to Your Information  
Needs, Quickly and Conveniently  
NEWS 3 JAN 25 Annual Reload of MEDLINE database  
NEWS 4 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is  
Now Available for Download  
NEWS 5 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing  
of Author Abstracts  
NEWS 6 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN  
NEWS 7 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content  
and Features  
NEWS 8 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail  
Addresses  
NEWS 9 APR 02 CAS Registry Number Crossover Limits Increased to  
500,000 in Key STN Databases  
NEWS 10 APR 02 PATDPAFULL: Application and priority number formats  
enhanced  
NEWS 11 APR 02 DWPI: New display format ALLSTR available  
NEWS 12 APR 02 New Thesaurus Added to Derwent Databases for Smooth  
Sailing through U.S. Patent Codes  
NEWS 13 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding  
Coverage back to 1948  
NEWS 14 APR 07 CA/CAPLUS CLASS Display Streamlined with Removal of  
Pre-IPC 8 Data Fields  
NEWS 15 APR 07 50,000 World Traditional Medicine (WTM) Patents Now  
Available in CAPLUS  
NEWS 16 APR 07 MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:24:24 ON 13 MAY 2010

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.32	1.32

FILE 'REGISTRY' ENTERED AT 15:27:49 ON 13 MAY 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2010 HIGHEST RN 1222633-86-4  
DICTIONARY FILE UPDATES: 12 MAY 2010 HIGHEST RN 1222633-86-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10585553 str 1.str

L1 STRUCTURE UPLOADED

=> s l1 sss full

FULL SEARCH INITIATED 15:28:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 489 TO ITERATE

100.0% PROCESSED 489 ITERATIONS 24 ANSWERS  
SEARCH TIME: 00.00.01

L2 24 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	191.54	192.86

FILE 'CAPLUS' ENTERED AT 15:28:21 ON 13 MAY 2010  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 13 May 2010 VOL 152 ISS 20  
FILE LAST UPDATED: 12 May 2010 (20100512/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12

L3 84 L2

=> s 13 and antibacterial

127633 ANTIBACTERIAL

4133 ANTIBACTERIALS

128838 ANTIBACTERIAL

(ANTIBACTERIAL OR ANTIBACTERIALS)

L4 5 L3 AND ANTIBACTERIAL

=> d 14 1-4 ibib ab hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:477075 CAPLUS

DOCUMENT NUMBER: 149:99230

TITLE: In vitro anti-biofilm activity of macelignan isolated from *Myristica fragrans* Houtt. against oral primary colonizer bacteria

AUTHOR(S): Yanti; Rukayadi, Yaya; Kim, Kyu-Hoi; Hwang, Jae-Kwan

CORPORATE SOURCE: Department of Biotechnology, Yonsei University, Seoul, 120-749, S. Korea

SOURCE: Phytotherapy Research (2008), 22(3), 308-312

CODEN: PHYREH; ISSN: 0951-418X

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In early dental plaque formation, oral primary colonizers such as *Streptococcus mutatis*, *Streptococcus sanguis* and *Actinomyces viscosus* are initially attached to the pellicle-coated tooth surface to form a biofilm. The study aimed to determine the efficacy of macelignan, isolated from nutmeg (*Myristica fragrans* Houtt.), in removing each single oral primary biofilm in vitro on a polystyrene 96-well microtiter plate. Four biofilm growth phases (4, 12, 20 and 24 h) were evaluated in this study after treatment with macelignan at various concns. (0.2, 2 and 10 µg/mL) and exposure times (5, 10 and 30 min). Anti-biofilm activity of macelignan was measured as the percentage of the remaining biofilm absorbance after macelignan treatment in comparison with the untreated control. At 24 h of biofilm growth, *S. mutatis*, *A. viscosus* and *S. sanguis* biofilms were reduced by up to 30%, 30% and 38%, resp., after treatment with 10 µg/mL macelignan for 5 min. Increasing the treatment time to 30 min resulted in a reduction of more than 50% of each of the single primary biofilms. The results indicate that macelignan is a potent natural anti-biofilm agent against oral primary colonizers.

IT 107534-93-0, Macelignan


RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); BIOL (Biological study); OCCU (Occurrence)

(in vitro anti-biofilm activity of macelignan isolated from *Myristica fragrans* against oral primary colonizer bacteria)

RN 107534-93-0 CAPLUS

CN Phenol, 4-[(2S,3R)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxy-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:149861 CAPLUS

DOCUMENT NUMBER: 148:466894

TITLE: Antibacterial lignans and triterpenoids from  
Rostellularia procumbens

AUTHOR(S): Zhang, Yongli; Bao, Fukai; Hu, Juanjuan; Liang,  
Shengwang; Zhang, Yu; Du, Guanhua; Zhang, Caijun;  
Cheng, Yongxian

CORPORATE SOURCE: State Key Laboratory of Phytochemistry and Plant  
Resources in West China, Kunming Institute of Botany,  
Chinese Academy of Sciences, Kunming, Peop. Rep. China  
SOURCE: Planta Medica (2007), 73(15), 1596-1599  
CODEN: PLMEAA; ISSN: 0032-0943

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB One new lignan, rostellulin A (1), four known lignans, justin B (2),  
justicidin C (3), cilinaphthalide A (4), and justicidin A (5), and four  
known triterpenoids, ursolic acid (6), euscaphic acid (7),  
2 $\alpha$ -hydroxyursolic acid (8), and tormentic acid (9), have been  
isolated from the whole plants of Rostellularia procumbens. Their  
structures were established on the basis of spectral data, including  
extensive NMR expts. To our knowledge, compds. 6-9 are known compds. but  
not previously isolated from R. procumbens; 4 was previously reported from  
other Rostellularia species. Antibacterial activities of 1-9  
were evaluated against eight bacterial strains with the agar dilution method,  
and they were found to possess antimicrobial activity with MIC values in  
the range of 1.56-100  $\mu$ g/mL. None of the lignans exhibited cytotoxic  
activity against HCT-8 and Bel-7402 cells at concns. up to 5  $\mu$ g/mL.


IT 202655-27-4P, Justin B

RL: BSU (Biological study, unclassified); NPO (Natural product  
occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU  
(Occurrence); PREP (Preparation)  
(isolation and identification of antibacterial lignans and  
triterpenoids from Rostellularia procumbens)

RN 202655-27-4 CAPLUS

CN 1,4-Butanediol, 2-(1,3-benzodioxol-5-ylmethyl)-3-[(4-hydroxy-3,5-  
dimethoxyphenyl)methyl]-, 1,4-diacetate, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:398671 CAPLUS

DOCUMENT NUMBER: 146:4016

TITLE: Anticariogenic activity of macelignan isolated from *Myristica fragrans* (nutmeg) against *Streptococcus mutans*

AUTHOR(S): Chung, J. Y.; Choo, J. H.; Lee, M. H.; Hwang, J. K.

CORPORATE SOURCE: Department of Biomaterials Science and Engineering, Yonsei University, Seoul, S. Korea

SOURCE: Phytomedicine (2006), 13(4), 261-266

CODEN: PYTOEY; ISSN: 0944-7113

PUBLISHER: Elsevier GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The occurrence of dental caries is mainly associated with oral pathogens, especially cariogenic *Streptococcus mutans*. Preliminary antibacterial screening revealed that the extract of *Myristica fragrans*, widely cultivated for the spice and flavor of foods, possessed strong inhibitory activity against *S. mutans*. The anticariogenic compound was successfully isolated from the methanol extract of *M. fragrans* by repeated silica gel chromatog., and its structure was identified as macelignan by instrumental anal. using 1D-NMR, 2D-NMR and EI-MS. The min. inhibitory concentration (MIC) of macelignan against *S. mutans* was 3.9  $\mu\text{g/mL}$ , which was much lower than those of other natural anticariogenic agents such as 15.6  $\mu\text{g/mL}$  of sanguinarine, 250  $\mu\text{g/mL}$  of eucalyptol, 500  $\mu\text{g/mL}$  of menthol and thymol, and 1000  $\mu\text{g/mL}$  of Me salicylate. Macelignan also possessed preferential activity against other oral microorganisms such as *Streptococcus sobrinus*, *Streptococcus salivarius*, *Streptococcus sanguis*, *Lactobacillus acidophilus* and *Lactobacillus casei* in the MIC range of 2-31.3  $\mu\text{g/mL}$ . In particular, the bactericidal test showed that macelignan, at a concentration of 20  $\mu\text{g/mL}$ , completely inactivated *S. mutans* in 1 min. The specific activity and fast-effectiveness of macelignan against oral bacteria strongly suggest that it could be employed as a natural antibacterial agent in functional foods or oral care products.

IT 107534-93-0, Macelignan


RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(anticariogenic activity of macelignan isolated from *Myristica fragrans* (nutmeg) against *Streptococcus mutans*)

RN 107534-93-0 CAPLUS

CN Phenol, 4-[(2S,3R)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxy-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS  
RECORD (19 CITINGS)  
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2005:696726 CAPLUS  
DOCUMENT NUMBER: 143:159638  
TITLE: Method and composition for treating acne using lignan  
compounds  
INVENTOR(S): Hwang, Jae-Kwan; Chung, Jae-Youn; Chung, Hee-Chul;  
Park, Kyung-Min  
PATENT ASSIGNEE(S): Newtree Industry Co., Ltd., S. Korea  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005070402	A1	20050804	WO 2005-KR45	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005073027	A	20050713	KR 2004-1207	20040108
JP 2007524666	T	20070830	JP 2006-549118	20050107
US 20090192217	A1	20090730	US 2006-585553	20060706
CN 101410100	A	20090415	CN 2005-80002069	20060707
PRIORITY APPLN. INFO.:			KR 2004-1207	A 20040108
			WO 2005-KR45	W 20050107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 143:159638

AB The present invention relates to a method and composition for treating acne  
using lignan compds. represented by Formula 1. More particularly, the

invention relates to an antibacterial composition against acne-causing bacteria, containing lignan compds., as well as a method for treating acne using the same. The lignan compds. of the invention are excellent not only in the antibacterial activity of inhibiting the growth of acne-causing bacteria, but also in thermal stability. Accordingly, the lignan compds. may be useful as antibacterial agents against the acne-causing bacteria, and acne treatment agents.

IT 107534-93-0, Macelignan  
 RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (treating acne using lignan compds.)  
 RN 107534-93-0 CAPLUS  
 CN Phenol, 4-[(2S,3R)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxy-  
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:24:24 ON 13 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:27:49 ON 13 MAY 2010

L1 STRUCTURE UPLOADED  
 L2 24 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:28:21 ON 13 MAY 2010

L3 84 S L2  
 L4 5 S L3 AND ANTIBACTERIAL

=> s l3 and acne

9694 ACNE  
 2137 ACNES  
 11111 ACNE  
 (ACNE OR ACNES)

L5 1 L3 AND ACNE

=> s l3 and staphylococcus

89735 STAPHYLOCOCCUS  
 1 STAPHYLOCOCCUSES  
 89735 STAPHYLOCOCCUS  
 (STAPHYLOCOCCUS OR STAPHYLOCOCCUSES)

L6 3 L3 AND STAPHYLOCOCCUS

=> d 16 1-3 ibib ab hitstr

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:149861 CAPLUS

DOCUMENT NUMBER: 148:466894

TITLE: Antibacterial lignans and triterpenoids from  
Rostellularia procumbens

AUTHOR(S): Zhang, Yongli; Bao, Fukai; Hu, Juanjuan; Liang,  
Shengwang; Zhang, Yu; Du, Guanhua; Zhang, Caijun;  
Cheng, Yongxian

CORPORATE SOURCE: State Key Laboratory of Phytochemistry and Plant  
Resources in West China, Kunming Institute of Botany,  
Chinese Academy of Sciences, Kunming, Peop. Rep. China  
SOURCE: Planta Medica (2007), 73(15), 1596-1599  
CODEN: PLMEAA; ISSN: 0032-0943

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB One new lignan, rostellulin A (1), four known lignans, justin B (2),  
justicidin C (3), cilinaphthalide A (4), and justicidin A (5), and four  
known triterpenoids, ursolic acid (6), euscaphic acid (7),  
2 $\alpha$ -hydroxyursolic acid (8), and tormentic acid (9), have been  
isolated from the whole plants of Rostellularia procumbens. Their  
structures were established on the basis of spectral data, including  
extensive NMR expts. To our knowledge, compds. 6-9 are known compds. but  
not previously isolated from R. procumbens; 4 was previously reported from  
other Rostellularia species. Antibacterial activities of 1-9 were  
evaluated against eight bacterial strains with the agar dilution method, and  
they were found to possess antimicrobial activity with MIC values in the  
range of 1.56-100  $\mu$ g/mL. None of the lignans exhibited cytotoxic  
activity against HCT-8 and Bel-7402 cells at concns. up to 5  $\mu$ g/mL.

IT 202655-27-4P, Justin B


RL: BSU (Biological study, unclassified); NPO (Natural product  
occurrence); PUR (Purification or recovery); BIOL (Biological study); OCCU  
(Occurrence); PREP (Preparation)

(isolation and identification of antibacterial lignans and  
triterpenoids from Rostellularia procumbens)

RN 202655-27-4 CAPLUS

CN 1,4-Butanediol, 2-(1,3-benzodioxol-5-ylmethyl)-3-[(4-hydroxy-3,5-  
dimethoxyphenyl)methyl]-, 1,4-diacetate, (2R,3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
(3 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 2006:398671 CAPLUS  
 DOCUMENT NUMBER: 146:4016  
 TITLE: Anticariogenic activity of macelignan isolated from *Myristica fragrans* (nutmeg) against *Streptococcus mutans*  
 AUTHOR(S): Chung, J. Y.; Choo, J. H.; Lee, M. H.; Hwang, J. K.  
 CORPORATE SOURCE: Department of Biomaterials Science and Engineering, Yonsei University, Seoul, S. Korea  
 SOURCE: Phytomedicine (2006), 13(4), 261-266  
 CODEN: PYTOEY; ISSN: 0944-7113  
 PUBLISHER: Elsevier GmbH  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The occurrence of dental caries is mainly associated with oral pathogens, especially cariogenic *Streptococcus mutans*. Preliminary antibacterial screening

revealed that the extract of *Myristica fragrans*, widely cultivated for the spice and flavor of foods, possessed strong inhibitory activity against *S. mutans*. The anticariogenic compound was successfully isolated from the methanol extract of *M. fragrans* by repeated silica gel chromatog., and its structure was identified as macelignan by instrumental anal. using 1D-NMR, 2D-NMR and EI-MS. The min. inhibitory concentration (MIC) of macelignan

against *S. mutans* was 3.9 µg/mL, which was much lower than those of other natural anticariogenic agents such as 15.6 µg/mL of sanguinarine, 250 µg/mL of eucalyptol, 500 µg/mL of menthol and thymol, and 1000 µg/mL of Me salicylate. Macelignan also possessed preferential activity against other oral microorganisms such as *Streptococcus sobrinus*, *Streptococcus salivarius*, *Streptococcus sanguis*, *Lactobacillus acidophilus* and *Lactobacillus casei* in the MIC range of 2-31.3 µg/mL. In particular, the bactericidal test showed that macelignan, at a concentration of 20 µg/mL, completely inactivated *S. mutans* in 1 min. The specific activity and fast-effectiveness of macelignan against oral bacteria strongly suggest that it could be employed as a natural antibacterial agent in functional foods or oral care products.

IT 107534-93-0, Macelignan


RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(anticariogenic activity of macelignan isolated from *Myristica fragrans* (nutmeg) against *Streptococcus mutans*)

RN 107534-93-0 CAPLUS

CN Phenol, 4-[(2S,3R)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN  
ACCESSION NUMBER: 2005:696726 CAPLUS  
DOCUMENT NUMBER: 143:159638  
TITLE: Method and composition for treating acne using lignan compounds  
INVENTOR(S): Hwang, Jae-Kwan; Chung, Jae-Youn; Chung, Hee-Chul; Park, Kyung-Min  
PATENT ASSIGNEE(S): Newtree Industry Co., Ltd., S. Korea  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005070402	A1	20050804	WO 2005-KR45	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005073027	A	20050713	KR 2004-1207	20040108
JP 2007524666	T	20070830	JP 2006-549118	20050107
US 20090192217	A1	20090730	US 2006-585553	20060706
CN 101410100	A	20090415	CN 2005-80002069	20060707
PRIORITY APPLN. INFO.:			KR 2004-1207	A 20040108
			WO 2005-KR45	W 20050107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:159638


AB The present invention relates to a method and composition for treating acne using lignan compds. represented by Formula 1. More particularly, the invention relates to an antibacterial composition against acne-causing bacteria, containing lignan compds., as well as a method for treating acne using the same. The lignan compds. of the invention are excellent not only in the antibacterial activity of inhibiting the growth of acne-causing bacteria, but also in thermal stability. Accordingly, the lignan compds. may be useful as antibacterial agents against the acne-causing bacteria, and acne treatment agents.

IT 107534-93-0, Macelignan  
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treating acne using lignan compds.)

RN 107534-93-0 CAPLUS

CN Phenol, 4-[(2S,3R)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxy-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s macelignan  
32 MACELIGNAN  
1 MACELIGNANS  
L7 33 MACELIGNAN  
(MACELIGNAN OR MACELIGNANS)

=> s l7 and acne  
9694 ACNE  
2137 ACNES  
11111 ACNE  
(ACNE OR ACNES)  
L8 1 L7 AND ACNE

=> d 18

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2010 ACS on STN  
AN 2005:696726 CAPLUS  
DN 143:159638  
TI Method and composition for treating acne using lignan compounds  
IN Hwang, Jae-Kwan; Chung, Jae-Youn; Chung, Hee-Chul; Park, Kyung-Min  
PA Newtree Industry Co., Ltd., S. Korea  
SO PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070402	A1	20050804	WO 2005-KR45	20050107
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	KR 2005073027	A	20050713	KR 2004-1207	20040108
	JP 2007524666	T	20070830	JP 2006-549118	20050107
	US 20090192217	A1	20090730	US 2006-585553	20060706

CN 101410100 A 20090415 CN 2005-80002069 20060707  
PRAI KR 2004-1207 A 20040108  
WO 2005-KR45 W 20050107

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 143:159638

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 17 and bacteria

389789 BACTERIA

165 BACTERIAS

389880 BACTERIA

(BACTERIA OR BACTERIAS)

L9 3 L7 AND BACTERIA

=> d 19

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:477075 CAPLUS

DN 149:99230

TI In vitro anti-biofilm activity of macelignan isolated from  
Myristica fragrans Houtt. against oral primary colonizer bacteria

AU Yanti; Rukayadi, Yaya; Kim, Kyu-Hoi; Hwang, Jae-Kwan

CS Department of Biotechnology, Yonsei University, Seoul, 120-749, S. Korea

SO Phytotherapy Research (2008), 22(3), 308-312

CODEN: PHYREH; ISSN: 0951-418X

PB John Wiley & Sons Ltd.

DT Journal

LA English

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:24:24 ON 13 MAY 2010)

FILE 'REGISTRY' ENTERED AT 15:27:49 ON 13 MAY 2010

L1 STRUCTURE UPLOADED

L2 24 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:28:21 ON 13 MAY 2010

L3 84 S L2

L4 5 S L3 AND ANTIBACTERIAL

L5 1 S L3 AND ACNE

L6 3 S L3 AND STAPHYLOCOCCUS

L7 33 S MACELIGNAN

L8 1 S L7 AND ACNE

L9 3 S L7 AND BACTERIA